CXADR

CXADR Informations sur la molécule

Nom anglais	Calcium sensing receptor	Nombre de médicaments commercialisés	6
Nombre de médicaments cliniques	5	Alias de la cible	Parathyroid cell calcium-sensing receptor 1，FHH，FIH，HHC，Receptors， Calcium-Sensing，Extracellular calcium-sensing receptor，hCasR，GPRC2A，Calcium Sensing Receptor，Parathyroid Ca(2+)-Sensing Receptor 1，Severe Neonatal Hyperparathyroidism，Calcium-Sensing Receptor，HYPOC1，NSHPT，PCaR1，EIG8，HHC1，CaSR，CAR，Hypocalciuric Hypercalcemia 1
Phase de R&D la plus avancée	Approved

Nom anglais	Calcium sensing receptor
Alias de la cible	Parathyroid cell calcium-sensing receptor 1，FHH，FIH，HHC，Receptors， Calcium-Sensing，Extracellular calcium-sensing receptor，hCasR，GPRC2A，Calcium Sensing Receptor，Parathyroid Ca(2+)-Sensing Receptor 1，Severe Neonatal Hyperparathyroidism，Calcium-Sensing Receptor，HYPOC1，NSHPT，PCaR1，EIG8，HHC1，CaSR，CAR，Hypocalciuric Hypercalcemia 1
Nombre de médicaments commercialisés	6
Nombre de médicaments cliniques	5
Phase de R&D la plus avancée	Approved

CXADR Liste de produits

Attribut
Protein (1)
Bibliothèque de produits
En ligne (1)
Espèces
Human (1)
Étiquette
His Tag (1)
Marqueur
Unconjugated (1)

Numéro de produit	Espèces	Système d'expression	Description du produit	Structure protéique	Pureté	Caractéristiques	Pré-commande/Commande
CXR-H5222	Human	HEK293	Human CXADR / CAR Protein, His Tag				Ajouter au panier

Quantité totale1

CXADRContexte de la molécule

Coxsackie virus and adenovirus receptor (CXADR) is also known as CAR, is a type I transmembrane glycoprotein for group B coxsackie viruses and subgroup C adenoviruses, and belongs to the CTX family of the Ig superfamily. CAR is strongly expressed in the developing central nervous system. It functions as a homophilic and also as a heterophilic cell adhesion molecule through its interactions with extracellular matrix glycoproteins such as: fibronectin, agrin, laminin-1 and tenascin-R. Human CXADR protein contains a signal sequence, a extracellular domain (ECD) with a V type (D1) and a C2 type (D2) Iglike domain, a transmembrane segment and a intracellular domain. D1 is thought to be responsible for homodimer formation in trans within tight junctions, and is necessary and sufficient for adenovirus binding. Variants of CXADR are attached to the cell membrane by a GPI- anchor.

CXADRAlias de la molécule

CXADR,CAR,CAR4,6,HCAR

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
Encaleret sulfate	MK-5442; JTT-305; BBP-305; CLTX-305	Phase 3 Clinical	Japan Tobacco (Hong Kong) Ltd	Osteoporosis; Hypocalcemia; Osteoporosis, Postmenopausal; Hypoparathyroidism	Details
SHR-6508	SHR-6508	Phase 3 Clinical	Shanghai Hengrui Pharmaceutical Co Ltd	Hyperparathyroidism, Secondary; Kidney Diseases; Renal Insufficiency, Chronic; Hyperparathyroidism	Details
LNP-1892	LNP-1892	Phase 2 Clinical	Lupin Ltd	Hyperparathyroidism	Details
DS-9194b	DS-9194b	Phase 1 Clinical	Daiichi Sankyo Co Ltd	Osteoporosis	Details
RT-102(Rani)	RT-102	Phase 1 Clinical	Rani Therapeutics Holdings Inc	Osteoporosis	Details

Informations sur les médicaments commercialisés

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Plus ancien nom de marque	Pays d'approbation le plus ancien	Indication la plus ancienne	Société d'approbation la plus ancienne	Date d'approbation la plus ancienne	Indication	Essai clinique
Upacicalcet	SK-1403; AJT-240	Approved	Ajinomoto Co Inc	ウパシタ, Upasita	Japan	Hyperparathyroidism, Secondary	Sanwa Kagaku Kenkyusho Co Ltd	2021-06-23	Hyperparathyroidism, Secondary	Details
Parathyroid hormone (Shire)	SHP-634; ALX-111; 423562; NPSP-795; rhPTH (1-84); SHP-635; rhPTH-1-84; PTH (1-84); SB-423562; PTH 1-84; NPSP-558	Approved	Shire	Natpara, Preotact, Natpar	United States	Hypoparathyroidism	Nps Pharmaceuticals, Inc	2006-04-24	Osteoporosis; Bone Diseases, Endocrine; Osteoporosis, Postmenopausal; Hypocalcemia; Hypoparathyroidism; Hyperparathyroidism; Plaque psoriasis	Details
Cinacalcet Hydrochloride	AMG-073.HCl; NPS-1493; AMG-073; KRN-1493	Approved	Amgen Inc	Parareg, Sensipar, Mimpara, Regpara, 盖平, Sensipar/Mimpara	United States	Hypercalcemia; Hyperparathyroidism, Secondary	Amgen Inc	2004-03-08	Hyperparathyroidism, Secondary; Rejection of renal transplantation; Hypophosphatemia; Edema, Cardiac; Nephrosis; Renal Insufficiency; Parathyroid Neoplasms; Hypercalcemia; Kidney Diseases; Hyperparathyroidism, Primary; Prostatic Neoplasms; Osteomalacia; Renal Insufficiency, Chronic; Kidney Failure, Chronic; Hyperparathyroidism; Chronic Kidney Disease-Mineral and Bone Disorder	Details
Etelcalcetide Hydrochloride	ONO-5163; KAI-4169; AMG-416; KAI-4169-HCl	Approved	Amgen Inc	Parsabiv	EU	Hyperparathyroidism, Secondary	Amgen Europe Bv	2016-11-11	Hyperparathyroidism, Secondary; Edema, Cardiac; Renal Insufficiency, Chronic; Kidney Failure, Chronic	Details
Strontium Ranelate	S-12911; S-12911-2; FK-481	Approved	Laboratoires Servier	Osseor, Protos, Protelos, 欧思美	Mainland China	Osteoporosis, Postmenopausal	Les Laboratoires Servier	2004-09-20	Osteoporosis, Postmenopausal	Details
Evocalcet	KHK-7580; MT-4580	Approved	Mitsubishi Tanabe Pharma Corp	Orkedia	Japan	Hyperparathyroidism, Secondary	Kyowa Hakko Kirin Co Ltd	2018-03-23	Hyperparathyroidism, Secondary; Parathyroid Neoplasms; Hyperparathyroidism, Primary; Hyperparathyroidism	Details